Denali Therapeutics EPS misses by $0.15, beats on revenue

|About: Denali Therapeutics Inc. (DNLI)|By:, SA News Editor

Denali Therapeutics (NASDAQ:DNLI): Q2 GAAP EPS of -$0.61 misses by $0.15.

Revenue of $4.2M (+154.5% Y/Y) beats by $0.28M.

Press Release

Subscribe for full text news in your inbox